颅内磷酸盐尿性间叶肿瘤:一种罕见实体的系统性文献综述
本文报告一例由颅底磷酸盐尿性间叶肿瘤(PMT)颅内延伸致肿瘤性骨软化症(TIO)的病例,并遵循PRISMA指南系统检索PubMed,纳入29例颅内PMT病例。作者认为手术是当前首选治疗,1年随访结局良好,但近25%病例可能复发。
要点
- 颅内PMT罕见,多位于前颅窝,常表现为TIO伴骨软化、疼痛、无力及多发骨折。
核心结论
- 颅底PMT伴颅内延伸是极罕见肿瘤,多数患者为中年成人,肿瘤主要位于前颅窝;手术是当前首选治疗,1年随访结局最佳,但近25%病例可能复发。
研究设计与样本
- 病例报告联合系统性文献综述,检索遵循PRISMA指南,在PubMed以标题/摘要关键词「Phosphaturic mesenchymal tumor」和「Osteomalacia」检索,筛选颅内或颅底肿瘤,共纳入29例颅内PMT病例。
临床怎么用
- 作者认为手术是当前首选治疗,1年随访结局最佳,但近25%病例可能复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phosphaturic Mesenchymal Tumors (PMTs) are rare mesenchymal neoplasms known for producing Tumor-induced Osteomalacia (TIO). TIO is an uncommon paraneoplastic syndrome characterized by radiographic evidence of inadequate bone mineralization and analytical abnormalites. METHODS: We sought to present a case of TIO caused by skull base PMT with intracranial extension, manifesting with pain, progressive weakness, and multiple bone fractures. Furthermore, a systematic review was performed, following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A search was conducted in PubMed database with title/abstract keywords "Phosphaturic mesenchymal tumor" and "Osteomalacia." Search results were reviewed looking for intracranial or skull base tumors. RESULTS: Our systematic review included 29 reported cases of intracranial PMT. In the reviewed cases there was a significative female predominance with 22 cases (75,86%). Osteomalacia was presented in 25 cases (86,20%). Bone fractures were present in 10 cases (34,48%). The most common site of involvement was the anterior cranial fossa in 14 cases (48,27%). Surgery was performed in 27 cases (93,10%) with previous tumor embolization in 4 cases (13,79%). Total recovery of the presenting symptoms in the first year was achieved in 21 cases (72,41%). Recurrence of the disease was described in 6 cases (25%). CONCLUSIONS: Skull base PMTs with intracranial extension are extremely rare tumors. Most patients are middle-aged adults with a PMT predominantly located in anterior cranial fossa. Surgery is the current treatment of choice with optimal outcome at 1-year follow-up, although recurrence could be present in almost 25% of the cases.
引用
- Sánchez Muñoz R, Sanmillan JL, Vidal Sarró N, et al. Intracranial Phosphaturic Mesenchymal Tumors: A Systematic Literature Review of a Rare Entity. World Neurosurg. 2024. PMID: 38561034. doi:10.1016/j.wneu.2024.03.138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。